For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Leucine Enkephalin (Leu-Enkephalin) vs Pinealon

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Leucine Enkephalin (Leu-Enkephalin)Pinealon
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asLeu5-enkephalin, YGGFL, L-enkephalin, endogenous opioid pentapeptideEDR, Glu-Asp-Arg, Pineal tripeptide
EvidenceResearch-stageResearch-stage
Dosing range0.1mg–1mg mg, Intranasal or SC; extremely short half-life requires frequent dosing or continuous delivery100mcg–300mcg mcg, Once daily (evening, given melatonin/sleep effects)
AdministrationIntranasal, Subcutaneous injection, Intraventricular (research only)Subcutaneous injection, Intranasal, Oral (sublingual for better absorption)
Key side effectsTolerance development with repeated use (opioid receptor class effect), Mild euphoria (δ-opioid mediated), Nausea (at high doses), Constipation (opioid class effect at high doses)Generally well-tolerated, Drowsiness if dosed during the day, Vivid dreams (common — melatonin pathway activation), Mild headache (uncommon)
Cited sources2 references2 references

Key differences

  • Administration: Leucine Enkephalin (Leu-Enkephalin) — Intranasal, Subcutaneous injection, Intraventricular (research only); Pinealon — Subcutaneous injection, Intranasal, Oral (sublingual for better absorption).
  • Dosing units differ: Leucine Enkephalin (Leu-Enkephalin) is dosed in mg, Pinealon in mcg — they operate at different scales.
  • Frequency: Leucine Enkephalin (Leu-Enkephalin) is typically Intranasal or SC; extremely short half-life requires frequent dosing or continuous delivery; Pinealon is Once daily (evening, given melatonin/sleep effects).

How each works

Leucine Enkephalin (Leu-Enkephalin)

Leu-enkephalin was one of the first endogenous opioid peptides characterized, following the discovery of opioid receptors in 1973. It preferentially activates δ-opioid receptors (DOR) over μ-opioid receptors (MOR), producing analgesia, modulation of GABA release, and reward pathway activation. Enkephalinase (neprilysin/NEP, CD10) cleaves the Gly-Phe bond within ~2 minutes IV, necessitating stable analogues or NEP inhibitors for research applications.

Pinealon

Like other peptide bioregulators from the Khavinson group, Pinealon is proposed to work by penetrating the nuclear membrane and interacting directly with histones and promoter regions to regulate transcription. In vitro studies show Pinealon increases synthesis of serotonin and melatonin precursors in pinealocytes and upregulates antioxidant enzyme expression in neuronal cells. Animal studies demonstrate reduced neuronal apoptosis after hypoxic stress and improved performance in cognitive tasks. Clinical observations from Russian gerontology practice suggest benefits for insomnia, age-related cognitive decline, and neurological recovery.

Read the full Leucine Enkephalin (Leu-Enkephalin) profileRead the full Pinealon profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.